{"id":"recombinant-grass-pollen","safety":{"commonSideEffects":[{"rate":null,"effect":"Local injection site reactions (itching, swelling, erythema)"},{"rate":null,"effect":"Oral allergy syndrome or local oral symptoms"},{"rate":null,"effect":"Systemic allergic reactions"},{"rate":null,"effect":"Anaphylaxis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This recombinant allergen immunotherapy product contains engineered grass pollen proteins designed to shift immune responses from allergic (Th2-mediated) to tolerant (Treg-mediated) pathways. By administering gradually increasing doses of the recombinant allergen, the therapy aims to induce immune tolerance and reduce allergic symptoms upon natural grass pollen exposure. This approach is characteristic of allergen-specific immunotherapy (AIT) for IgE-mediated grass pollen allergy.","oneSentence":"Recombinant grass pollen allergen extract desensitizes the immune system to grass pollen by inducing immune tolerance through repeated controlled exposure.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:31:32.209Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Grass pollen-induced allergic rhinitis and/or allergic asthma"}]},"trialDetails":[{"nctId":"NCT02643641","phase":"PHASE2","title":"Effect of Different Pre-seasonal BM32 Dosings on the Induction of a Protective Immune Response","status":"COMPLETED","sponsor":"Biomay AG","startDate":"2016-01","conditions":"Hypersensitivity","enrollment":130},{"nctId":"NCT01538979","phase":"PHASE2","title":"Phase II Study of Grass Pollen Allergy Vaccine BM32","status":"COMPLETED","sponsor":"Biomay AG","startDate":"2012-03","conditions":"Grass Pollen Allergy","enrollment":181},{"nctId":"NCT01350635","phase":"PHASE1, PHASE2","title":"Skin Test Study of BM32","status":"COMPLETED","sponsor":"Biomay AG","startDate":"2011-05","conditions":"Hypersensitivity","enrollment":60},{"nctId":"NCT01353755","phase":"PHASE3","title":"2nd Pivotal Study rPhleum - Adults and Adolescents With Rhinoconjunctivitis +/-Controlled Asthma","status":"COMPLETED","sponsor":"Allergopharma GmbH & Co. KG","startDate":"2009-10","conditions":"Rhinoconjunctivitis, Allergic Asthma","enrollment":195},{"nctId":"NCT00671268","phase":"PHASE3","title":"Evaluation of Safety and Efficacy of Specific Immunotherapy With Recombinant Major Allergens of Timothy Grass Pollen Adsorbed Onto Aluminium-hydroxide in Patients With IgE-mediated Allergic Rhinoconjunctivitis +/- Controlled Asthma","status":"COMPLETED","sponsor":"Allergopharma GmbH & Co. KG","startDate":"2008-03","conditions":"Rhinoconjunctivitis","enrollment":256},{"nctId":"NCT00666341","phase":"PHASE2","title":"Dose-Response-Study With a Recombinant Cocktail of Phleum (rPhleum) Allergens","status":"COMPLETED","sponsor":"Allergopharma GmbH & Co. KG","startDate":"2007-09","conditions":"Type I-Allergy","enrollment":50},{"nctId":"NCT00309036","phase":"PHASE3","title":"Safety and Efficacy of Recombinant Grass Pollen Allergen Cocktail in the Treatment of Allergic Rhinoconjunctivitis","status":"COMPLETED","sponsor":"Allergopharma GmbH & Co. KG","startDate":"2004-01","conditions":"Allergy","enrollment":""},{"nctId":"NCT01445002","phase":"PHASE2","title":"Safety and Dose Finding Trial of BM32 in Subjects Suffering From Grass Pollen Allergy","status":"COMPLETED","sponsor":"Biomay AG","startDate":"2011-10","conditions":"Grass Pollen Allergy","enrollment":79}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":21,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Recombinant grass pollen","genericName":"Recombinant grass pollen","companyName":"Allergopharma GmbH & Co. KG","companyId":"allergopharma-gmbh-co-kg","modality":"Biologic","firstApprovalDate":"","aiSummary":"BM32 is a recombinant, hypoallergenic grass pollen vaccine used to treat conditions such as hypersensitivity, rhinoconjunctivitis, and allergic asthma. It works as a hyaluronic acid hydrolytic enzyme, breaking down hyaluronic acid, and is classified as a hydrolytic enzyme drug.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}